Literature DB >> 8691269

Bone marrow dosimetry: regional variability of marrow-localizing antibody.

G Sgouros1, I M Jureidini, A M Scott, M C Graham, S M Larson, D A Scheinberg.   

Abstract

UNLABELLED: In radiolabeled antibody therapy, imaging and biopsy-based methods are used to estimate marrow activity concentration when the administered antibody localizes to the marrow. Absorbed dose estimates obtained using such measurements may be subject to large variability due to the potential for regional differences in marrow activity concentration. This variability was examined in ten patients with leukemia after administration of 131I-labeled HuM195 antibody.
METHODS: Regions of interest were drawn around the head and neck of the humerus and femur (both sides) and around lumbar vertebra 3 (L3) and 4 (L4) on a series of planar images collected at multiple times postadministration of the antibody. A single exponential fit to each attenuation-corrected, time-activity curve was obtained to estimate clearance half-life and the back-extrapolated percent injected activity.
RESULTS: The activity concentration in the femoral head and neck (mean and s.d. = 0.04 +/- 0.02 %ID/g) was not significantly different than that measured in L3 and L4 (0.06 +/- 0.02% ID/g) but was not significantly lower than the concentrations measured in the humeral head and neck regions (0.07 +/- 0.03 %ID/g, p < 0.05). Although half-life estimates differing by more than a factor of 2 were observed in half-life between regions overall. S-factors were used for individual marrow regions to determine the mean absorbed dose to marrow in the femoral and humeral heads and the lumbar vertebrae (L3 and L4) which were 0.66 +/- 0.3, 1.0 +/- 0.3 and 2.2 +/- 0.5 mGy/MBq (2.4, 3.8 and 8.3 rad/mCi), respectively.
CONCLUSION: A single value is generally quoted for the absorbed dose delivered to the red marrow following marrow-localizing radiolabeled antibody administration. These results suggest that the regional marrow dose may differ significantly from the mean.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8691269

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.

Authors:  Cecilia Hindorf; Gerhard Glatting; Carlo Chiesa; Ola Lindén; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

2.  First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK.

Authors:  Silvano Gnesin; Periklis Mitsakis; Francesco Cicone; Emmanuel Deshayes; Vincent Dunet; Augusto F Gallino; Marek Kosinski; Sébastien Baechler; Franz Buchegger; David Viertl; John O Prior
Journal:  EJNMMI Res       Date:  2017-05-18       Impact factor: 3.138

3.  Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy.

Authors:  Wietske Woliner-van der Weg; Rafke Schoffelen; Robert F Hobbs; Martin Gotthardt; David M Goldenberg; Robert M Sharkey; Cornelis H Slump; Winette Ta van der Graaf; Wim Jg Oyen; Otto C Boerman; George Sgouros; Eric P Visser
Journal:  EJNMMI Phys       Date:  2015-02-24

4.  A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity.

Authors:  Johanna Svensson; Tobias Rydén; Linn Hagmarker; Jens Hemmingsson; Bo Wängberg; Peter Bernhardt
Journal:  EJNMMI Phys       Date:  2016-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.